午夜剧场

I graduated from the 午夜剧场 School of Medicine in 1996. Excluding six years working at affiliated hospitals and three years studying in the United States, I worked at 午夜剧场 Hospital for over 17 years before assuming my current position in June 2022. Although I am still in the middle of my journey as a clinician, I strive to value the connections between people in every situation.

In terms of research, unlike in the past, the development of information technology has made it difficult for a small number of people to conduct research and produce high-quality results on their own. Comprehensive analysis of big data is essential to achieving significant results. Therefore, it is important to conduct joint research with various experts to advance research projects. I believe that the key to moving research forward together is to carry it out based on relationships of trust built by valuing human connections. During my time at 午夜剧场, I served as a respiratory physician, and during the COVID-19 pandemic, I served as a sub-leader of the COVID-19 medical team at 午夜剧场 Hospital.

Even during the COVID-19 pandemic, the faculty at 午夜剧场 were full of a desire to promote research and produce new findings. Under the leadership of the Dean of the School of Medicine, the "Donner Project" was launched to clarify the pathology of COVID-19. I was involved in the research as the person in charge of clinical operations. Thanks to the close collaboration built on trust within the university, procedures for research consent and specimen collection were quickly established, and various results have been published. Furthermore, I served as the administrative lead for the representative institution in the Coronavirus Pandemic Control Task Force, which was established by Dean Takanori Kanai and succeeded by Professor Koichi Fukunaga of the Department of Respiratory Medicine.

In addition to the Juku, experts from various specialized fields such as infectious diseases, molecular genetics, and genomic medicine from Tokyo Medical and Dental University and Osaka University collaborated, forming a research group with over 100 participating institutions. Our paper, which identified the disease-susceptibility gene DOCK2 and demonstrated its molecular severity, was accepted by the journal Nature last year, and research is still ongoing. I truly feel that this is made possible by our mutual trust. I learned that even during the COVID-19 pandemic, it is important to work together to clarify academic questions and share them with the world.

Moving forward, I hope to continue my research while "valuing connections between people" and never forgetting my sense of gratitude.